(Q34386133)

1 August 2017

title

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop (English)

1 reference

1 August 2017

0 references

De Gruttola VG

1

1 reference

1 August 2017

Clax P

2

1 reference

1 August 2017

DeMets DL

3

1 reference

1 August 2017

Downing GJ

4

1 reference

1 August 2017

Ellenberg SS

5

1 reference

1 August 2017

Friedman L

6

1 reference

1 August 2017

Gail MH

7

1 reference

1 August 2017

Prentice R

8

1 reference

1 August 2017

Wittes J

9

1 reference

1 August 2017

Zeger SL

10

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Contemporary Clinical Trials

1 August 2017

published in

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

485-502

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Statistical validation of intermediate endpoints for chronic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Estimating the proportion of treatment effect explained by a surrogate marker.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

The validation of surrogate endpoints in meta-analyses of randomized experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

On meta-analytic assessment of surrogate outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900153-2

7 January 2021

10.1016/S0197-2456(01)00153-2

Identifiers

DOI

1 reference

release_yb74h2qkkna5ve4daeu2cy6q4u

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yb74h2qkkna5ve4daeu2cy6q4u

24 November 2022

mapped directly with Wikidata item

1 reference